Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

May 31, 2028

Conditions
Developmental and Epileptic EncephalopathiesEpileptic SpasmsGenetic EpilepsyNeonatal and Infant Epilepsy
Interventions
DRUG

Ketogenic diet

The ketogenic diet formula will be KetoVie®, supplied by Ajinomoto Cambrooke. Ketogenic diet ratio will aim to achieve ketosis, with a minimum level of beta-hydroxybutyrate of 1.0mmol/L. Ratios of ketogenic diet generally range from 1:1 to 4:1. Ratio will increase per standard clinical care for ketogenic diet initiation. For the trial we will aim to reach a maximum of 4:1 by the 6 week follow-up visit, but stopping at a lower ratio if BHB is ≥ 5mmol/L, CO2 ≤ 18 mmol/L, for tolerance, or to meet protein needs. A minimum 1:1 ratio is required to continue in the trial. Ratios higher than 1:1 are often required to obtain ketosis of ideally 2-5mmol/L in infants.

Trial Locations (1)

02115

RECRUITING

Boston Children's Hospital, Boston

All Listed Sponsors
collaborator

Boston Children's Hospital Translational Research Program (TRP) Pappendick Family Therapeutic Acceleration Award

UNKNOWN

lead

Heather Olson

OTHER